BARLETTA, VALERIA TERESA
 Distribuzione geografica
Continente #
NA - Nord America 643
AS - Asia 190
EU - Europa 116
OC - Oceania 4
AF - Africa 1
SA - Sud America 1
Totale 955
Nazione #
US - Stati Uniti d'America 635
CN - Cina 63
IT - Italia 51
IN - India 47
SG - Singapore 45
TR - Turchia 21
DE - Germania 18
CA - Canada 8
FI - Finlandia 8
GB - Regno Unito 8
IR - Iran 6
SE - Svezia 6
UA - Ucraina 6
AU - Australia 4
BG - Bulgaria 4
NL - Olanda 4
ES - Italia 3
ID - Indonesia 3
IE - Irlanda 3
AZ - Azerbaigian 2
RO - Romania 2
RS - Serbia 2
UZ - Uzbekistan 2
AR - Argentina 1
GR - Grecia 1
JP - Giappone 1
MA - Marocco 1
Totale 955
Città #
Fairfield 89
Wilmington 49
Ashburn 47
Seattle 38
Woodbridge 35
Cambridge 33
Chandler 33
Singapore 33
Dearborn 28
Houston 27
Princeton 25
New York 22
Beijing 20
Rome 19
Boston 12
Plano 12
Lawrence 10
San Paolo di Civitate 10
Ann Arbor 9
Bremen 9
Kozlu 9
San Diego 9
Norwalk 8
St Louis 8
Cagliari 6
Millbury 5
Toronto 5
Andover 4
Ankara 4
Sofia 4
Adelaide 3
Albano Laziale 3
Des Moines 3
Dorchester 3
Dublin 3
Edinburgh 3
Falls Church 3
Jakarta 3
Kahramanmaraş 3
Munich 3
Móstoles 3
Nanjing 3
Santa Clara 3
Sinop 3
Stockholm 3
Baku 2
Belgrade 2
Bühl 2
Charlestown 2
Guangzhou 2
Hefei 2
Indore 2
London 2
Mannheim 2
Ottawa 2
Phoenix 2
Redwood City 2
Tashkent 2
Tehran 2
Amsterdam 1
Baotou 1
Bergamo 1
Buffalo 1
Chengdu 1
East Orange 1
Elâzığ 1
Falkenstein 1
Federal 1
Florence 1
Fuzhou 1
Glasgow 1
Hebei 1
Jiaxing 1
Kayseri 1
Kunming 1
Leiden 1
Miami 1
Mississauga 1
Nanchang 1
Ningbo 1
Orchard Park 1
Providence 1
Qazvin 1
Quzhou 1
Rabat 1
Riva 1
Secaucus 1
Shenzhen 1
Somerville 1
Southend 1
Thessaloniki 1
Tokyo 1
Zhengzhou 1
Totale 729
Nome #
Effect on cognition of estroprogestins combined with Interferon Beta in multiple sclerosis: analysis of secondary outcomes from a randomised controlled trial 84
Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis. 71
Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis 71
Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective? 61
Mood and coping in clinically isolated syndrome and multiple sclerosis. 60
Relationship between prolactin plasma levels and white matter volume in women with multiple sclerosis 60
Oral contraceptives combined with interferon β in multiple sclerosis 58
In vivo analyses of the correlates of cortical and white matter pathology in patients with multiple sclerosis by quantitative 7 Tesla and 3 Tesla MRI and molecular imaging. 49
Evidence of diffuse cerebellar neuroinflammation in multiple sclerosis by 11 C-PBR28 MR-PET 48
The relevance of 7-Tesla paramagnetic rim lesions in patients with multiple sclerosis 42
In vivo characterization of cerebellar microglia activation in multiple sclerosis by combined 11C-PBR28 MR-PET and 7 Tesla MRI. 37
Microglia activation in cerebellum increases with proximity to the fourth ventricle in progressive MS. 36
Whole brain in vivo axonal diameter mapping in multiple sclerosis 36
Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis. J Neurol Sci. 2012 Dec 15;323(1-2):104-12. doi: 10.1016/j.jns.2012.08.027. Epub 2012 Sep 21. 34
Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: results from a longitudinal study. J Neurol Sci. 2014 Feb 15;337(1-2):180-5. doi: 10.1016/j.jns.2013.12.006. Epub 2013 Dec 26. 28
Two determinants of late disability progression in multiple sclerosis: early inflammatory disease and old age in damaged brain. 25
Thalamic atrophy and its substrates in multiple sclerosis by ultra-high field MRI 22
In vivo characterization of cortical lesion demyelination and remyelination in early multiple sclerosis by quantitative 7 Tesla MRI 22
null 21
null 20
Characterization of outer and inner spinal cord pathology in multiple sclerosis by 7 Tesla imaging. ECTRIMS 2019 20
Profiles of cortical and white matter lesion inflammation in multiple sclerosis by combined 11C-PBR28 and 7 T imaging 19
null 16
null 16
null 12
Characterization of thalamic lesions and their correlates in multiple sclerosis by ultra-high-field MRI. 10
The relevance of multiple sclerosis cortical lesions on cortical thinning and their clinical impact as assessed by 7.0-T MRI. 10
Ultra-high field 7 T imaging in multiple sclerosis. 9
7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis. 9
Totale 1.006
Categoria #
all - tutte 3.298
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.298


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020201 0 0 0 0 15 40 53 30 25 20 7 11
2020/202163 4 11 0 1 1 1 0 20 11 1 10 3
2021/2022190 7 12 17 8 29 7 5 20 15 16 25 29
2022/2023142 44 21 4 13 18 11 1 6 12 0 10 2
2023/2024160 15 25 6 13 9 30 9 8 1 14 21 9
2024/202587 12 23 16 31 5 0 0 0 0 0 0 0
Totale 1.006